| abstract |
The present invention relates to certain fused pyrazole derivatives of formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit, for example, pharmacological properties useful as agonists for the RUP25 receptor. The present invention is also directed to pharmaceutical compositions comprising the compounds of the present invention and to the treatment of metabolic related disorders including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes and syndrome X, and the like. Methods of using the compounds and compositions of the invention are provided. Additionally, the present invention also provides other active agents such as α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolic enhancers, angiotensin converting enzymes ( ACE) inhibitors, insulin secretion enhancers, and DP receptor antagonists and the like, together with the use of the compounds of the invention.n n n <Formula Ia> |